

**Form 51-102F3
Material Change Report**

Item 1 Name and Address of Company

PEGASUS MERCANTILE INC. (Formerly Xtacy Therapeutics Corp.) (the “Company”)
1100 – 1111 Melville Street
Vancouver, BC V6E 3V6

Item 2 - Date of Material Change

November 5, 2024

Item 3 News Release

A news release was issued and disseminated on November 4, 2024, and filed on SEDAR+ (www.sedarplus.ca) and with the CSE.

Item 4 Summary of Material Change

The Company announced that a bulletin was issued by the CSE noting the effective date for its name and Symbol change to Pegasus Mercantile Inc. will be at the open of markets on Tuesday, Nov 5, 2024. Its stock symbol on the CSE will be changed to “LOAN”. The new CUSIP and ISIN numbers will be 70557Y105 and CA70557Y1051 respectively.

Item 5 Full Description of Material Change

See the News Release attached as Schedule “A”.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7 Omitted Information

Not applicable.

Item 8 Executive Officer

The following senior officer of the Company is knowledgeable about the material change and this report:

Meris Kott, CEO and Director
Email: info@xtacytherapeutics.com
Phone: 604-484-0355

Item 9 Date of Report

November 5, 2024

SCHEDULE "A"



Update

(Xtacy Therapeutics Corp.)

Vancouver: November 2, 2024 –Xtacy Therapeutics Corp (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company)

Xtacy Therapeutics Corp. wishes to update the status of its name change to **Pegasus Mercantile Inc.** (“Pegasus”) with a new stock symbol of **“LOAN”**. The CSE has issued a bulletin today noting that the effective date for the name and Symbol change will be at the open of markets on **TUESDAY NOVEMBER 5, 2024**. The new Cusip 70557Y105 will be effective at that time.

The Change marks a very important day for the Company with the new nomenclature. There are no changes to the Company strategy, however the investee companies have accelerated their business plans and their needs have changed. As an incubator and project generator, it is the role of Pegasus to help our clients increase their current valuations and grow organically to the next cycle in their lifespan. In prior press releases we indicated the intent of some portfolio companies to go public. Such disclosure indicates only their stated intentions to us, and each is responsible for making their unique way onto the public exchanges. The Pegasus team will take a more active role with the management of our current and new clients providing key advisory services. The Company will continue to provide business and financial plans, strategy, and merger/acquisition candidates with joint venture corporate partners and others involving financial and business related services.

“Our people invest in cutting edge biotechnology research and technology. Our strategy allows us to place investments into companies from start up to commercialization. We focus on scalability and differentiation which can potentially bring radical benefits to consumers and patients who need life changing treatments. We are extremely proud to be part of this evolving sector and look forward to bringing greater value to our shareholder base,” said Meris Kott, CEO.

About Pegasus Mercantile:

Pegasus is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

For further information visit website:

www.pegasusmercantile.com

Contact Meris Kott CEO

info@pegasusmercantile.com (561)212-3323

Further information about the Company is available on www.SEDARplus.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.